MedTrace Logo

NWRD09 for HPV-16 Related Cervical HSIL

NCT07047989 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-07-02

No results posted yet for this study

Summary

This is a single-arm, open label, multi-center clinical study to evaluate the safety, tolerability and immunogenicity HPV16 targeted mRNA therapeutic vaccine (NWRD09) in HPV16 related cervical high-grade squamous intraepithelial lesions (HSlL).

Conditions

  • High-grade Squamous Intraepithelial Lesion (HSIL)

Interventions

BIOLOGICAL

NWRD09 injection

NWRD09 administered by intramuscular injection

Sponsors & Collaborators

  • Newish Biotech (Wuxi) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-12
Primary Completion
2026-07-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07047989 on ClinicalTrials.gov